Ireland· IE-PA-PA2299/027/003
Endoxana Coated Tablets 50 mg
A cyclophosphamide product containing cyclophosphamide monohydrate, registered in Ireland by Baxter Holding B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Cyclophosphamide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01AA01 (cyclophosphamide), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Cyclophosphamide · ATC L01AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cyclophosphamide costs, country by country.
Normalised to the WHO defined daily dose (0.25 g), the median price runs from $1.57 in France to $14.12 in Switzerland — a ×9.0 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cyclophosphamide · price per daily dose (0.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$14.12
- IT Italy$1.58
- FR France$1.57
The record
At a glance
HPRA (Ireland)- Active substance
- Cyclophosphamide monohydrate
- Manufacturer
- Baxter Holding B.V.
- Country
- Ireland (IE)
- ATC code
- L01AA01
- ATC class
- Cyclophosphamide
- Defined daily dose
- 0.25 g, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA2299/027/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
541 interactions on record for cyclophosphamide.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cyclophosphamide · interactions on record
541 records
- 34 severe
- 172 moderate
- 29 minor
- 304 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- CidofovirJ05AB12severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cyclophosphamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaENDOXANBaxter Oncology GmbH, Halle
- NetherlandsEndoxan 50 mg omhulde tablettenEuro Registratie Collectief B.V.
- FinlandSendoxanBaxter Oy
- BelgiumEndoxan 50 mgBaxter
- SpainGENOXAL 50 mg COMPRIMIDOS RECUBIERTOSBaxter S.L.
- FranceENDOXAN 50 mg, comprimé enrobéBAXTER
- United StatesCyclophosphamideBluePoint Laboratories
- United KingdomCyclophosphamide 1000mg/250ml in Sodium chloride 0.9% infusion bagsSpecial Order
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Cyclophosphamid Sandoz, Endoxan
- Belgium · Cyclofosfamide Accord, Cyclophosphamide Hikma
- Bulgaria · Cyclophosphamide Sandoz, Ендоксан
- Cyprus · Cyclophosphamide Accord, Endoxan
- Czechia · Cyclophosphamide Accord, Endoxan
- Germany · Cyclophosphamid Accord, Cyclophosphamid Beta
- Denmark · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Estonia · Cyclophosphamide Accord, Endoxan
- Spain · Ciclofosfamida Accord, Ciclofosfamida Dr. Reddy
- Finland · Cyclophosphamide Accord, Sendoxan
- France · Cyclophosphamide Accord, Cyclophosphamide Reddy Pharma
- United Kingdom (Northern Ireland) · Cyclophosphamide Accord Healthcare, Cyclophosphamide Accord-Uk
- Greece · Endoxan
- Croatia · Ciklofosfamid Accord, Endoxan
- Hungary · Endoxan
- Iceland · Sendoxan
- Italy · Ciclofosfamide Accord, Cyclophosphamide Monohydrate Seacross
- Lithuania · Cyclophosphamide Accord Healthcare, Endoxan
- Luxembourg · Endoxan
- Latvia · Cyclophosphamide Accord, Endoxan
- Malta · Endoxana, Endoxana Injection
- Netherlands · Cyclofosfamide Accord, Cyclofosfamide Hikma
- Norway · Cyclophosphamide Accord, Sendoxan
- Poland · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Portugal · Ciclofosfamida Accord, Ciclofosfamida Hikma
- Romania · Ciclofosfamidă Accord, Ciclofosfamidă Dr. Reddy’s
- Sweden · Cyclophosphamide Accord, Cyclophosphamide Sandoz
- Slovenia · Endoxan
- Slovakia · Endoxan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3c15c30d-3b76-4712-9260-446fb9f6e70a GET /v1/drugs/3c15c30d-3b76-4712-9260-446fb9f6e70a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01AA",
"L01AA01"
],
"strength": null,
"pa_number": "PA2299/027/003",
"substances": [
"Cyclophosphamide monohydrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "26/06/2008",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about cyclophosphamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.